> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Triple Combination Drug Approved for Diabetes
- URL: https://www.fdaweb.com/triple-combination-drug-approved-for-diabetes/
- Published: 2020-01-28T12:00:00.000Z
- Updated: 2026-09-14T16:00:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145948

FDA has approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly’s Trijardy XR (empagliflozin/linagliptin/metformin HCl) to lower blood sugar in adults with Type 2 diabetes, along with diet and exercise. Trijardy XR comprises three Type 2 diabetes medicines in one pill, including Jardiance, Tradjenta and metformin extended release. Approval is based on data from two randomized open-label trials that assessed the bioequivalence of empagliflozin, linagliptin and metformin fixed-dose combination tablets and their individual components in healthy adults, the companies say. The combination product’s safety profile was found to be consistent with its individual components, they add.